Document Detail


Comparison of the prognostic predictive value of the TIMI, PAMI, CADILLAC, and GRACE risk scores in STEACS undergoing primary or rescue PCI.
MedLine Citation:
PMID:  22281285     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION AND OBJECTIVES: We sought to compare the predictive value of the Thrombolysis In Myocardial Infarction (TIMI), Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC), Primary Angioplasty in Myocardial Infarction (PAMI), and Global Registry for Acute Coronary Events (GRACE) scores for the outcome of ST-segment elevation acute coronary syndrome undergoing urgent percutaneous coronary intervention.
METHODS: We performed a retrospective analysis of a cohort composed of all consecutive patients with ST-segment elevation acute coronary syndrome treated by urgent percutaneous coronary intervention between 2006 and 2010 (n=1503). TIMI, PAMI, CADILLAC, and GRACE risk scores were calculated for each patient according to different clinical variables. We assessed the predictive accuracy of these scores for death, reinfarction, and target-vessel revascularization at 30 days and 1 year, using the C statistic, which was obtained by means of logistic regression and ROC curves.
RESULTS: The TIMI, PAMI, CADILLAC and GRACE showed an excellent predictive value for 30-day and 1-year mortality (C statistic range, 0.8-0.9), with superiority of the TIMI, CADILLAC, and GRACE risk models. The performance of these 4 scores was poor for both reinfarction and target-vessel revascularization (C statistic, 0.5-0.6).
CONCLUSIONS: The TIMI, PAMI, CADILLAC, and GRACE scores provide excellent information to stratify the risk of mortality in patients treated by percutaneous coronary intervention. The TIMI, CADILLAC, and GRACE models have higher predictive accuracy. The usefulness of these models for reinfarction and target-vessel revascularization prediction is questionable.
Authors:
Elizabet Méndez-Eirín; Xacobe Flores-Ríos; Fernando García-López; Alberto J Pérez-Pérez; Rodrigo Estévez-Loureiro; Pablo Piñón-Esteban; Guillermo Aldama-López; Jorge Salgado-Fernández; Ramón A Calviño-Santos; José M Vázquez Rodríguez; Nicolás Vázquez-González; Alfonso Castro-Beiras
Related Documents :
23324915 - Is percutaneous coronary intervention as effective as bypass surgery in left main stem ...
9420835 - Left ventricular diastolic function: physiology, methods of assessment, and clinical si...
21671145 - Left ventricular dyssynchrony assessment by phase analysis from gated pet-fdg scans.
11894155 - Flow pattern of the superior caval vein in children after closure of atrial septal defe...
3773225 - Is it possible to rule out extensive anterior myocardial infarction in the absence of a...
18836265 - Frequency and clinical significance of acute bilateral cerebellar infarcts.
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2012-01-26
Journal Detail:
Title:  Revista española de cardiología (English ed.)     Volume:  65     ISSN:  1885-5857     ISO Abbreviation:  Rev Esp Cardiol (Engl Ed)     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-02-22     Completed Date:  2012-07-02     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  101587954     Medline TA:  Rev Esp Cardiol (Engl Ed)     Country:  Spain    
Other Details:
Languages:  eng; spa     Pagination:  227-33     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Sociedad Española de Cardiología. Published by Elsevier Espana. All rights reserved.
Affiliation:
Unidad de Hemodinámica, Servicio de Cardiología, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Coronary Syndrome / surgery
Aged
Angioplasty, Balloon, Coronary*
Antibodies, Monoclonal / therapeutic use*
Cohort Studies
Coronary Disease / complications,  mortality,  surgery*
Female
Humans
Immunoglobulin Fab Fragments / therapeutic use*
Logistic Models
Male
Middle Aged
Myocardial Infarction / drug therapy*,  surgery*
Myocardial Revascularization
Platelet Aggregation Inhibitors / therapeutic use*
Postoperative Complications / drug therapy*,  mortality
Predictive Value of Tests
Prognosis
ROC Curve
Recurrence
Registries
Retrospective Studies
Risk Assessment
Thrombolytic Therapy*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunoglobulin Fab Fragments; 0/Platelet Aggregation Inhibitors; X85G7936GV/abciximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Self-reported practices, attitudes and levels of training of practitioners in the English NHS Stop S...
Next Document:  Data integration and systems biology approaches for biomarker discovery: Challenges and opportunitie...